|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Panoilia E, Schindler E, Samantas E,
Aravantinos G, Kalofonos HP, Christodoulou C, Patrinos GP, Friberg
LE and Sivolapenko G: A pharmacokinetic binding model for
bevacizumab and VEGF165 in colorectal cancer patients. Cancer
Chemother Pharmacol. 75:791–803. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Santoro V, Jia R, Thompson H, Nijhuis A,
Jeffery R, Kiakos K, Silver AR, Hartley JA and Hochhauser D: Role
of reactive oxygen species in the abrogation of oxaliplatin
activity by cetuximab in colorectal cancer. J Natl Cancer Inst.
108:djv3942015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dawson H and Lugli A: Molecular and
pathogenetic aspects of tumor budding in colorectal cancer. Front
Med (Lausanne). 2:112015.PubMed/NCBI
|
|
5
|
Roskoski R Jr: The ErbB/HER family of
protein-tyrosine kinases and cancer. Pharmacol Res. 79:34–74. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Veikkolainen V, Vaparanta K, Halkilahti K,
Iljin K, Sundvall M and Elenius K: Function of ERBB4 is determined
by alternative splicing. Cell Cycle. 10:2647–2657. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Muraoka-Cook RS, Sandahl MA, Strunk KE,
Miraglia LC, Husted C, Hunter DM, Elenius K, Chodosh LA and Earp HS
III: ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids
and exert opposing effects on the mammary epithelium in vivo. Mol
Cell Biol. 29:4935–4948. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lédel F, Stenstedt K, Hallström M,
Ragnhammar P and Edler D: HER3 expression in primary colorectal
cancer including corresponding metastases in lymph node and liver.
Acta Oncol. 54:480–486. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kurppa KJ, Denessiouk K, Johnson MS and
Elenius K: Activating ERBB4 mutations in non-small cell lung
cancer. Oncogene. 35:1283–1291. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Williams CS, Bernard JK, Demory Beckler M,
Almohazey D, Washington MK, Smith JJ and Frey MR: ERBB4 is
over-expressed in human colon cancer and enhances cellular
transformation. Carcinogenesis. 36:710–718. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mohd Nafi SN, Generali D, Kramer-Marek G,
Gijsen M, Strina C, Cappelletti M, Andreis D, Haider S, Li JL,
Bridges E, et al: Nuclear HER4 mediates acquired resistance to
trastuzumab and is associated with poor outcome in HER2 positive
breast cancer. Oncotarget. 5:5934–5949. 2014.PubMed/NCBI
|
|
12
|
Machleidt A, Buchholz S, Diermeier-Daucher
S, Zeman F, Ortmann O and Brockhoff G: The prognostic value of Her4
receptor isoform expression in triple-negative and Her2 positive
breast cancer patients. BMC Cancer. 13:4372013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim JY, Jung HH, Do IG, Bae S, Lee SK, Kim
SW, Lee JE, Nam SJ, Ahn JS, Park YH and Im YH: Prognostic value of
ERBB4 expression in patients with triple negative breast cancer.
BMC Cancer. 16:1382016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Canfield K, Li J, Wilkins OM, Morrison MM,
Ung M, Wells W, Williams CR, Liby KT, Vullhorst D, Buonanno A, et
al: Receptor tyrosine kinase ERBB4 mediates acquired resistance to
ERBB2 inhibitors in breast cancer cells. Cell Cycle. 14:648–655.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao WJ: The expression and localization
of neuregulin-1 (Nrg1) in the gastrointestinal system of the rhesus
monkey. Folia Histochem Cytobiol. 51:38–44. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Papaleo F, Yang F, Paterson C, Palumbo S,
Carr GV, Wang Y, Floyd K, Huang W, Thomas CJ, Chen J, et al:
Behavioral, neurophysiological, and synaptic impairment in a
transgenic neuregulin1 (NRG1-IV) murine schizophrenia model. J
Neurosci. 36:4859–4875. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Paatero I, Lassus H, Junttila TT, Kaskinen
M, Bützow R and Elenius K: CYT-1 isoform of ErbB4 is an independent
prognostic factor in serous ovarian cancer and selectively promotes
ovarian cancer cell growth in vitro. Gynecol Oncol. 129:179–187.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nielsen TO, Poulsen SS, Journe F, Ghanem G
and Sorensen BS: HER4 and its cytoplasmic isoforms are associated
with progression-free survival of malignant melanoma. Melanoma Res.
24:88–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wali VB, Gilmore-Hebert M, Mamillapalli R,
Haskins JW, Kurppa KJ, Elenius K, Booth CJ and Stern DF:
Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic
mice reveals isoform-specific roles in mammary gland development
and carcinogenesis. Breast Cancer Res. 16:5012014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Munk M, Memon A, Poulsen SS, Borre M, Nexo
E and Sorensen BS: The HER4 isoform JM-a/CYT2 relates to improved
survival in bladder cancer patients but only if the estrogen
receptor α is not expressed. Scand J Clin Lab Invest. 73:503–513.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kiuchi T, Ortiz-Zapater E, Monypenny J,
Matthews DR, Nguyen LK, Barbeau J, Coban O, Lawler K, Burford B,
Rolfe DJ, et al: The ErbB4 CYT2 variant protects EGFR from
ligand-induced degradation to enhance cancer cell motility. Sci
Signal. 7:ra782014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bae JA, Kho DH, Sun EG, Ko YS, Yoon S, Lee
KH, Ahn KY, Lee JH, Joo YE, Chung IJ, et al: Elevated Coexpression
of KITENIN and the ErbB4 CYT-2 isoform promotes the transition from
colon adenoma to carcinoma following APC loss. Clin Cancer Res.
22:1284–1294. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nielsen TO, Sorensen S, Dagnæs-Hansen F,
Kjems J and Sorensen BS: Directing HER4 mRNA expression towards the
CYT2 isoform by antisense oligonucleotide decreases growth of
breast cancer cells in vitro and in vivo. Br J Cancer.
108:2291–2298. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Han ME, Kim HJ, Shin DH, Hwang SH, Kang CD
and Oh SO: Overexpression of NRG1 promotes progression of gastric
cancer by regulating the self-renewal of cancer stem cells. J
Gastroenterol. 50:645–656. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Park J, Sarode VR, Euhus D, Kittler R and
Scherer PE: Neuregulin 1-HER axis as a key mediator of
hyperglycemic memory effects in breast cancer. Proc Natl Acad Sci
USA. 109:pp. 21058–21063. 2012; View Article : Google Scholar : PubMed/NCBI
|
